DETERMINATION OF INTERLEUKIN-28B GENE POLYMORPHIC VARIANTS IN PATIENTS WITH MIXED CHC/HIV INFECTION
- Autores: FAZYLOV V.H.1, CHULANOV V.P2, MANAPOVA E.R1, KARANDASHOVA I.V2, DOLGIN V.A2, BESHIMOV A.T3
-
Afiliações:
- Kazan State Medical University
- Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
- Republican Center for Prevention and Control of AIDS and Infectious Diseases, Ministry of Health of the Republic of Tatarstan
- Edição: Nº 3 (2013)
- Páginas: 29-32
- Seção: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/276819
- ID: 276819
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Objective. To identify single nucleotide polymorphism (SNP) at the rs8099917 and rs12979860 loci of the interleukin 28B (IL-28B) gene in patients with mixed chronic hepatitis C/HIV (CHC/HIV) infection and to estimate its value in the rate of virologic response to combination antiviral therapy with Peg-IFN-a-2a and ribavirin. Subjects and methods. An AmpliSens® Genoscreen-IL28В-FL kit was used to identify SNP at the rs8099917 and rs12979860 loci of the interleukin 28B (IL-28B) gene in 43 patients (67% were males) aged 32.91±0.58 years with the duration of HCV and HIV infection being less than 10 years and 6.89±0.53 years, respectively. Results. There were rather common favorable IL-28B genotypes CCand TTand their combination, in HCVgenotype 3 in particular; the samepatients werefound to have a morepronounced inflammatory process with a high HCVRNA load. Conclusion. The identification of IL-28B SNP (rs12979860 and rs8099917) in HIV infected individuals is of practical importance in achieving virologic responses to antiviral therapy for CHC. A sustained virologic response was achieved in 80.95% of the patients with favorable genotypes CC and TT.
Texto integral
Sobre autores
Vildan FAZYLOV
Kazan State Medical University
Email: vildan47@rambler.ru
V. CHULANOV
Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
Email: vladimir.chulanov@pcr.ru
E. MANAPOVA
Kazan State Medical University
Email: elveram@yandex.ru
I. KARANDASHOVA
Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
Email: inga.karandashova@pcr.ru
V. DOLGIN
Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
Email: vadim.dolgin@pcr.ru
A. BESHIMOV
Republican Center for Prevention and Control of AIDS and Infectious Diseases, Ministry of Health of the Republic of Tatarstan
Email: beshimov@rambler.ru
Bibliografia
- Chung R.T., Andersen J., Volberding P., Robbins G.K., Liu T., Sherman K.E. et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 2004; 351: 451—459.
- Muir A.J., Bornstein J.D., Killenberg P.G. Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for thetreatment of chronic hepatitis C in blacks andnon-Hispanic whites. N. Engl. J. Med. 2004; 350: 2265—2271.
- Missiha S., Heathcote J., Arenovich T., Khan K. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am. J. Gastroenterol. 2007; 102: 2181—2188.
- Conjeevaram H.S., Fried M.W., Jeffers L.J., Terrault N.A., Wiley-Lucas T.E., Afdhal N. et al. Peginterferon and ribavirin treatment in African American and Caucasian American patientswith hepatitis C genotype 1. Gastroenterology 2006; 131: 470—477.
- Ge D., Fellay J., Thompson A. J. et al. Genetic variation in IL28 B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461(7262): 399—401.
- Rallön N.I., Naggie S., Benito J.M., Medrano J., Restrepo C., Goldstein D. et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24(8): F23—F29.
- Rauch A., Kutalik Z., Descombes P. et al. Genetic variation in IL28 B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138(4): 1338—1345.
- Aparicio E., Parera M., Franco S., Perez-Alvarez N., Tural C. et al. IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-patients. PLoS ONE 2010; 5(10): e13771.
- Rallon N.I., Soriano V., Naggie S., Restrepo C., Goldstein D., Vispo Е. et al. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS 2011; 25: 1025—1033.
- Labarga P., Barreiro P., Mira J.A., Vispo E., Rallon N., Neukam K. et al. Impact of IL28B polymorphisms on response to peginterferon plus ribavirin in HIV-HCV coinfected patients with prior non-response or relapse. AIDS 2011; 25: 1131—1133.
- Younossi Z.M., Birerdinc A., Estep M., Stepanra M., Afendy А., Baranova А. The impact of IL28B genotype on the gene expression profile ofpatients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. Journal of Translational Medicine 2012, 10:25 doi: 10.1186/1479—5876—10—25.
- McCarthy J., Li J., Thompson A., Suchindran S., Lao X.Q., Patel K. et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307—2314.
Arquivos suplementares
